CARD11 and neoplasm: Previous research also proved that deletion of the CADR11 gene (alias CARMA1) in regulatory T cells could produce IFN-γ leading to dramatical anti-tumor effects, and contributed positively to the ICI therapies (Di Pilato et al., 2019).